Core Viewpoint - The controversy surrounding the collagen content in the product "Human-Like Recombinant Collagen" from the brand Kefu Mei, owned by the company Giant Bio, has raised significant concerns regarding product integrity and testing methods [1][2][3]. Group 1: Controversy Details - KOL "Dr. Big Mouth" (Hao Yu) claimed that tests showed the collagen content in Kefu Mei's product was only 0.0177% using HPLC amino acid quantification [1]. - Giant Bio responded by stating their tests indicated collagen content greater than 0.1%, contradicting the claims made by Hao Yu, but third-party test results are still pending [2]. - Hao Yu further questioned Giant Bio's testing methods, suggesting that the use of the biuret method could lead to inflated results due to the presence of sodium polyglutamate in the product [3]. Group 2: Previous Issues and Impact - This is not the first controversy for Kefu Mei in 2023, as the brand was previously accused of illegally adding epidermal growth factor (EGF), which led to a public trust crisis [4][5]. - The Shaanxi Provincial Drug Administration investigated the previous claims and found no violations after sampling [6]. - The outcome of the current controversy is crucial for Giant Bio's future performance, as Kefu Mei is projected to generate revenue of 4.542 billion yuan in 2024, contributing over 80% to the company's total revenue [6]. Group 3: Market Reaction - Despite the unresolved testing results, the controversy has significantly impacted Giant Bio's stock price [7]. - As of May 29, Giant Bio's market capitalization was 72.9 billion HKD, having lost 12.8 billion HKD since early May [8].
巨子生物胶原蛋白“缺量罗生门”追踪